A phase IIb, randomised, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes
-
- Ferrannini
- Creator
Details
-
- CRID
- 1370004238396142080
-
- Data Source
-
- Crossref